Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Álvarez‐Larrán, C. Besses, Carmen Burgaleta et al.|Haematologica|2016Cited by 149
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemiaArturo Pereira, Juan Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo et al.|Annals of Hematology|2015Cited by 54
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression riskFrancisca Ferrer‐Marín, Ana B. Arroyo, Beatríz Bellosillo et al.|Leukemia|2020Cited by 23
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of MyelofibrosisIrene Pastor‐Galán, Francisco Cervantes, Juan Carlos Hernández‐Boluda et al.|Medicina Clínica (English Edition)|2020Cited by 12
Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de MielofibrosisIrene Pastor‐Galán, Francisco Cervantes, Juan Carlos Hernández‐Boluda et al.|Medicina Clínica|2020Cited by 5